A previous analysis based on The Cancer Genome Atlas (TCGA) RNA sequencing data suggested lower expression of ACSL1 influences metabolic reprogramming and contributes to the better survival of patients with isocitrate dehydrogenase 1 (IDH1) mutant glioma (Zhou et al., 2019). The gene discussed is ACSL1; the disease is central nervous system cancer.